Navigation Links
Peregrine Pharmaceuticals Reports Financial Results for the First Quarter of Fiscal Year 2009
Date:9/9/2008

Total current assets 19,682,000 19,843,000

PROPERTY:

Leasehold improvements 669,000 669,000

Laboratory equipment 4,140,000 4,140,000

Furniture, fixtures and office equipment 919,000 919,000

5,728,000 5,728,000

Less accumulated depreciation and

amortization (3,803,000) (3,670,000)

Property, net 1,925,000 2,058,000

Other assets 1,201,000 1,156,000

TOTAL ASSETS $22,808,000 $23,057,000

PEREGRINE PHARMACEUTICALS, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS (continued)

JULY 31, APRIL 30,

2008 2008

Unaudited

LIABILITIES AND STOCKHOLDERS' EQUITY

CURRENT LIABILITIES:

Accounts payable $3,134,000 $2,060,000

Accrued clinical trial site fees 305,000 237,000

Accrued legal and accounting fees 210,000 450,000

Accrued royalties and license fees 151,000 222,000

Accrued payroll and related costs 955,000 1,084,000

Capital lease obligation, current

portion 22,000 22,000

Deferred revenue 4,021,000 2,196,000

Deferred government contract revenue 980,000 -

Customer deposits 1,898,000 838,000

Other current liabilities 336,000 331,000

Total current liabilities
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Peregrine Pharmaceuticals to Report First Quarter FY 2009 Financial Results
2. Peregrine Pharmaceuticals Receives Letter from NASDAQ Citing Failure to Regain Compliance with Minimum Bid Price Rule
3. Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2008
4. Peregrine Pharmaceuticals Awarded DTRA Contract Worth up to $44.4 Million to Develop Bavituximab for Viral Hemorrhagic Fevers
5. Peregrine Pharmaceuticals Presents Promising Phase I Data at ASCO and Provides Clinical Update on Its Phase II Bavituximab Breast Cancer Study
6. Peregrine Pharmaceuticals Reports Studies Published in Science Highlight Key Role of Phosphatidylserine (PS) in Viral Infections
7. Peregrine Pharmaceuticals Announces Four Upcoming Presentations at the American Association for Cancer Research 2008 Annual Meeting
8. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
9. Peregrine Pharmaceuticals to Announce Third Quarter FY 2008 Financial Results
10. Publication in Clinical Cancer Research Confirms Ability of Peregrines Bavituximab to Target Tumor Blood Vessels with Excellent Specificity
11. Peregrine Pharmaceuticals Doses First Patient in Phase II Clinical Trial of Bavituximab in Patients With Advanced Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... Aug. 27, 2014 Guggenheim Securities, the investment ... announced the hiring of veteran equity analyst Charles "Tony" ... Mr. Butler will focus on the biotech/biopharma sector. ... wealth of experience and a broad network of relationships ... Managing Director and Head of Equities at Guggenheim Securities. ...
(Date:8/27/2014)... (PRWEB) August 27, 2014 Flagship Biosciences ... services to the pharmaceutical and medical device industries, ... The fast growing company has consolidated its histology ... and Boulder to Westminster, CO, just north of Denver. ... Lab, 7575 W. 103rd Ave., Suite 100, Westminster, CO ...
(Date:8/27/2014)... Research and Markets  has announced the addition of ... Report 2014" report to their offering. ... Report 2014 is a professional and in-depth study on ... spectrometer industry. The report provides a basic ... industry chain structure. The isotope ratio mass spectrometer market ...
(Date:8/27/2014)... MONMOUTH JUNCTION, N.J. , Aug. 27, 2014 /PRNewswire/ ... developing innovative drug delivery technologies, today announced that it ... New Jersey Business & Industry Association,s 2014 Awards ... Finalists were selected by an independent panel of judges ... member company volunteers. Award winners will be honored at ...
Breaking Biology Technology:Guggenheim Securities Hires Analyst Charles "Tony" Butler to Expand Healthcare Coverage 2Flagship Biosciences Announces Relocation and Expansion 2Global Stable Isotope Ratio Mass Spectrometer Industry Report 2014 2Tris Pharma Selected as an award winner in the New Jersey Business & Industry Association's 2014 Awards for Excellence 2
... 7 Interleukin Genetics,Inc. (Amex: ILI ), a ... genetic tests for sale to the,emerging personalized health market, ... 2007. The Company recorded revenue of $2.6 million ... for third quarter ended September 30,2006, a 92% increase. ...
... Symbol: MS, EDMONTON, Nov. 7 /PRNewswire-FirstCall/ - ... the treatment of multiple sclerosis (MS), today,announced that ... the,Company,s phase II MINDSET-01 trial of MBP8298 in ... and recommended that,the trial continue as per the ...
... Transgenomic Inc. (OTC,Bulletin Board: TBIO) announces the following Webcast: What: ... Conference Call, When: ... http://www.transgenomic.com/events.asp?id=6 , How: Live ... address above., ...
Cached Biology Technology:Interleukin Genetics, Inc. Reports Third Quarter 2007 Financial Results 2Interleukin Genetics, Inc. Reports Third Quarter 2007 Financial Results 3Interleukin Genetics, Inc. Reports Third Quarter 2007 Financial Results 4Interleukin Genetics, Inc. Reports Third Quarter 2007 Financial Results 5Interleukin Genetics, Inc. Reports Third Quarter 2007 Financial Results 6BioMS Medical's relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board 2Webcast Alert: Transgenomic Inc. Announces Third Quarter 2007 Earnings Release Conference Call Webcast 2
(Date:8/28/2014)... alert the world to Global Warming, has called for ... underground. He says that Carbon Capture, combined with limits ... avoid global warming getting out of control over the ... made the call during his presentation to the International ... meeting to discuss Carbon Capture and Storage. , ...
(Date:8/27/2014)... The mechanical force that a single fungal cell or ... small, but it plays a heavy role in setting up ... fact, it may not be too much of a stretch ... without the ability to respond to the touch of beneficial ... a professor of agronomy at the University of Wisconsin-Madison. ...
(Date:8/27/2014)... Reportlinker.com announces that a new market ... Law Enforcement Biometrics Market in North America ... About Biometrics Biometrics is a technology that ... their physical or behavioral patterns. It involves the ... as fingerprints, face recognition, DNA, palm print, hand ...
Breaking Biology News(10 mins):Global warming pioneer calls for CO2 to be taken from atmosphere and stored underground 2A touching story: The ancient conversation between plants, fungi and bacteria 2A touching story: The ancient conversation between plants, fungi and bacteria 3Law Enforcement Biometrics Market in North America 2014-2018 2Law Enforcement Biometrics Market in North America 2014-2018 3Law Enforcement Biometrics Market in North America 2014-2018 4Law Enforcement Biometrics Market in North America 2014-2018 5
... alAbsi, Ph.D., and a team of national collaborators have ... National Institutes of Health (NIH) for their research, AutoSense: ... alAbsi is a professor and founding director of Duluth ... SchoolDuluth Campus. , The project is among the first ...
... UC Davis Institute of Transportation Studies (ITS-Davis) will,co-sponsor ... Research to Practice" next month in Berkeley. ... local government,officials, private industry leaders, consultants and advisers, ... include: Innovative highway and ...
... million gift to the University of Michigan Health System is ... a mission of supporting fundamental research to advance the understanding ... of human diseases. The A. Alfred Taubman Medical Research ... for the retail pioneer whose funding and vision led to ...
Cached Biology News:Mustafa al'Absi Ph.D. and national team awarded major NIH grant 2$22 million gift from Alfred Taubman launches new biomedical research institute 2$22 million gift from Alfred Taubman launches new biomedical research institute 3$22 million gift from Alfred Taubman launches new biomedical research institute 4
Mouse monoclonal antibody to CDC2L5 - cell division cycle 2-like 5 (cholinesterase-related cell division controller)...
...
Our Histology, Immunohistochemistry and tissue arrays services include samples processing, different type of staning, histollogical stains, image analysis, tissue arrays, immunohistochemistry, etc....
Mouse monoclonal antibody to PDK2 - pyruvate dehydrogenase kinase, isoenzyme 2...
Biology Products: